EGFR Tyrosine kinase inhibitors (TKIs) can enhance the effect of MHC class I and II antigens on IFN-γ to increase CD8+T cells and DC cells levels, eliminate FOXP3+Tregs, inhibit Macrophage polarization to M2 phenotype, and reduce the PD-L1 expression in cancer cells (106). Here, FOXP3 is linked to cancer.